Coor

Coor

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Coor - Solid earnings despite softer sales

15 juli 2026

  • Adj. EBITA 1% vs cons, -2% vs ABGSCe, up 3% y-o-y
  • Continued margin increase, and org. growth to improve in Q4-Q1
  • Estimates likely largely unchanged; CC at 10:00 CET

Q2 results

Sales were stable but slightly below expectations (-2% vs ABGSCe and Infront consensus), driven by Norway and Denmark (6% and 3% below cons). Sales declined 3% y-o-y, whereof organic growth was -3% (positive in Sweden/Finland, and negative in Norway/Denmark). Adj. EBITA was SEK 170m, +3% y-o-y (-2% vs ABGSC and 1% vs cons), holding up better due to efficiency gains driving margin expansion (5.5% vs 5.2% last year). EBIT and net profit were in line with cons. FCF was weak due to seasonality and in line with last year (SEK -8m vs -9m last year) and the LTM cash conversion of 47% was in line with last quarter. Gearing of 2.5x was up slightly from 2.3x in Q1 due to the dividend and seasonal cash flow but down vs 2.9x last year.

Outlook and estimate changes

Management said it looks forward to the rest of 2026 with confidence and expect that its initiatives to boost add-on sales will bear fruit. Near-term, comps remain tough on organic growth due to the contract losses in Denmark and high variable volumes in Norway in Q3 last year. But as these effects fade from Q4-Q1, we think Coor is well-positioned to come back to solid organic growth, while margins should continue to improve. We do not expect any material estimate changes on the back of the Q2 numbers.

Final thoughts

Overall, it was a solid report. The share has been weak into number, -14% L3M vs OMXSGI +3% and closest peer ISS +17%, and now trades at 10x adj. P/E and 10x EV/adj. EBITA on our 2027e vs its five-year average of 12x (NTM).

Management will host a presentation of the report at 10:00 CET, you can use this link to participate.

Deviations
Source: ABG Sundal Collier, Company data, Infront consensus

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-07-15 Infrea - Strong quarter but pegged to Netel Infrea Analys
2026-07-15 Coor - Solid earnings despite softer sales Coor Analys
2026-07-15 Svedbergs Group - Nordics and one-offs weigh Svedbergs G.. Analys
2026-07-14 Nexam Chemical - Solid Q2, profitability within r... Nexam Chemical Analys
2026-07-14 Nexam Chemical - Record sales and first positive ... Nexam Chemical Analys
2026-07-14 Eastnine - Warsaw to become the largest market Eastnine Analys
2026-07-13 Ascelia Pharma - CRL update Ascelia Pharma Analys
2026-07-13 Medicover - Steady as she goes Medicover Analys
2026-07-13 Arctic Paper - Pulp beats paper Arctic Paper Analys
2026-07-13 Studsvik - Gearing up for the new-build era Studsvik Analys
2026-07-10 StrongPoint - The American dream StrongPoint Analys
2026-07-10 Careium - The pressure valve starting to open Careium Analys
2026-07-10 StrongPoint - Solid Q2 performance StrongPoint Analys
2026-07-10 Careium - Growth's comeback tour continues Careium Analys
2026-07-09 Infrea - Road tripping with Netel Infrea Analys
2026-07-08 Alligo - Softer growth, but margin recovery conti... Alligo Analys
2026-07-08 Qliro - Key earnings drivers intact Qliro Analys
2026-07-07 Nexam Chemical - We expect a firmer sequential qu... Nexam Chemical Analys
2026-07-07 Eastnine - Adding in Warsaw Eastnine Analys
2026-07-06 Ovzon - No Q2 fireworks, but plenty of fuel Ovzon Analys